Sector
PharmaceuticalsOpen
₹4.15Prev. Close
₹4.07Turnover(Lac.)
₹1.15Day's High
₹4.15Day's Low
₹3.9952 Week's High
₹26.252 Week's Low
₹2.97Book Value
₹24.72Face Value
₹10Mkt Cap (₹ Cr.)
10.35P/E
25.88EPS
0.16Divi. Yield
030 Sep 2024
12:00 AM
AGM
Announcement Date: 30 Sep, 2024
3 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 25 | 25 | 25 | 23.36 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 36.82 | 36.43 | 35.35 | 36.51 |
Net Worth | 61.82 | 61.43 | 60.35 | 59.87 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 72.38 | 57.04 | 62.44 | 59.41 |
yoy growth (%) | 26.88 | -8.64 | 5.09 | 14.74 |
Raw materials | -42.91 | -33.6 | -40.42 | -36.01 |
As % of sales | 59.28 | 58.9 | 64.73 | 60.61 |
Employee costs | -6.92 | -4.59 | -5.62 | -4.29 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 0.86 | 0.07 | 1.07 | 5.26 |
Depreciation | -2.45 | -2.45 | -2.92 | -1.94 |
Tax paid | -0.33 | -0.14 | -0.28 | -1.25 |
Working capital | 4.97 | -5.1 | -0.87 | 14.24 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 26.88 | -8.64 | 5.09 | 14.74 |
Op profit growth | 23.63 | -7.39 | -37.21 | 30.48 |
EBIT growth | 20.24 | -4.71 | -44.86 | 38.9 |
Net profit growth | -551.24 | -111.05 | -83.64 | 79.07 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 61.7 | 68.59 | 77.87 | 73.73 | 57.09 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 61.7 | 68.59 | 77.87 | 73.73 | 57.09 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.44 | 0.73 | 0.54 | 0.28 | 0.86 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Suraj Zanwar
Independent Director
Sunil Kumar
Whole Time Director
Santosh Pimparkar
Milkat No 3339 BNo 1 Phursungi,
From Southside CS NO 227/2,
Maharashtra - 412308
Tel: 91-020-26982792
Website: http://www.cian.co
Email: cs@cian.co
Office No 56-2,
Pinnacle Busine.Park, Mahakali Caves Road,
Mumbai - 400093
Tel: 91-22-62638200
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Cian Healthcare Limited was originally incorporated as a Private Limited Company with the name of Cian Healthcare Private Limited on January 07, 2003. Subsequently, the Company was converted into a Pu...
Read More
Reports by Cian Healthcare Ltd
What is the Cian Healthcare Ltd share price today?
What is the Market Cap of Cian Healthcare Ltd?
What is the PE and PB ratio of Cian Healthcare Ltd?
What is the 52 Week High and Low of Cian Healthcare Ltd?
What is the CAGR of Cian Healthcare Ltd?
What is the shareholding pattern of Cian Healthcare Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.